Macrolides and β-lactam antibiotics enhance C3b deposition on the surface of multidrug-resistant Streptococcus pneumoniae strains by a LytA autolysin-dependent mechanism

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5534-5540

  Ramos Sevillano, Elisa ^a   Rodríguez Sosa, Cinthya ^b   Díez Martínez, Roberto ^a   Giménez, María José ^c   Olmedillas, Eduardo ^b   García, Pedro ^a   García, Ernesto ^a   Aguilar, Lorenzo ^c   Yuste, Jose ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AUTOLYSIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFDITOREN; CEFOTAXIME; CHLORAMPHENICOL; COMPLEMENT COMPONENT C3B; ERYTHROMYCIN; IMMUNOGLOBULIN G ANTIBODY; LEVOFLOXACIN; LYTA AUTOLYSIN; MACROLIDE; MIDECAMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD LEVEL; IMMUNE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMS; CELL WALL; COMPLEMENT C3B; CULTURE MEDIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; IMMUNE SERA; MACROLIDES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; STREPTOCOCCUS PNEUMONIAE;

EID: 84868028768     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01470-12     Document Type: Article

References (29)

1. Anderson R, et al. 2007. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J. Antimicrob. Chemother. 60:1155-1158.
2. Brown JS, et al. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc. Natl. Acad. Sci. U. S. A. 99:16969-16974.
3. Buyck JM, et al. 2012. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outermembrane permeability. Clin. Infect. Dis. doi:10.1093/cid/cis473.
4. Cafini F, et al. 2010. Enhanced in vivo activity of cefditoren in preimmunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One 5:e12041. doi:10.1371/journal.pone.0012041.
5. Casal J, et al. 2002. Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicrob. Agents Chemother. 46:1340-1344.
6. Dalia AB, Weiser JN. 2011. Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell. Host Microbe 10:486-496.
7. Darveau RP, Cunningham MD. 1990. Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa. J. Infect. Dis. 162:914-921.
8. Elliott TSJ, Rodgers FG. 1985. Morphological response and growth characteristics of Legionella pneumophila exposed to ampicillin and erythromycin. J. Med. Microbiol. 19:383-390.
9. Fenoll A, Martín Bourgon C, Muñoz R, Vicioso D, Casal J. 1991. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev. Infect. Dis. 13:56-60.
10. Fukuda Y, et al. 2006. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur. Respir. J. 27:1020-1025.
11. Hancock RE. 2005. Mechanisms of action of newer antibiotics for Grampositive pathogens. Lancet Infect. Dis. 5:209-218.
12. Imamura Y, et al. 2005. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. 49:1377-1380.
13. Labro MT.2000. Interference of antibacterial agents with phagocyte functions: immunomodulationor "immuno-fairy tales"? Clin. Microbiol. Rev. 13:615-650.
14. López R, García E. 2004. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Micro-biol. Rev. 28:553-580.
15. Morens DM, Folkers GK, Fauci AS. 2004. The challenge of emerging and re-emerging infectious diseases. Nature 430:242-249.
16. Moscoso M, García E, López R. 2006. Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J. Bacteriol. 188:7785-7795.
17. Pruul H, McDonald PJ. 1992. Potentiation of antibacterial activity of azithromycin and other macrolidesbynormal human serum. Antimicrob. Agents Chemother. 36:10-16.
18. Ramos-Sevillano E, Moscoso M, García P, García E, Yuste J. 2011. Nasopharyngeal colonization and invasive disease are enhancedby the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae. PLoS One 6:e23626. doi:10.1371/journal.pone.0023626.
19. Soriano F, et al. 2008. Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness. J. Antimicrob. Chemother. 62:1234-1240.
20. Tarragó D, et al. 2005. Specific antibodies, levofloxacin, and modulation of capsule-associated virulence in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49:3095-3096.
21. Tateda K, Hirakata Y, Furuya N, Ohno A, Yamaguchi K. 1993. Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:675-680.
22. Tomasz A. 1979. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu. Rev. Microbiol. 33:113-137.
23. Walport MJ. 2001. Complement. Second of two parts. N. Engl. J. Med. 344:1140-1144.
24. Yasuda Y, et al. 2007. Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. Antimicrob. Agents Chemother. 51:1741-1752.
25. Yuste J, Botto M, Paton JC, Holden DW, Brown JS. 2005. Additive inhibition of complement deposition bypneumolysin and PspA facilitates Streptococcus pneumoniae septicemia. J. Immunol. 175:1813-1819.
26. Yuste J, Fenoll A, Casal J, Giménez MJ, Aguilar L. 2002. Combined effect of specific antibodies (as serotherapy or preimmunization) and amoxicillin doses in treatment of Streptococcus pneumoniae sepsis in a mouse model. Antimicrob. Agents Chemother. 46:4043-4044.
27. Yuste J, et al. 2001. Enhanced decrease of blood colony counts by specific anti-pneumococcal antibodies in the presence of sub-inhibitory concentrations of amoxicillin. J. Antimicrob. Chemother. 48:594-595.
28. Yuste J, et al. 2002. Beta-lactam modification of the bacteraemic profile and its relationship with mortalityinapneumococcal mouse sepsis model. J. Antimicrob. Chemother. 49:331-335.
29. Yuste J, et al. 2008. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect. Immun. 76:3761-3770.